Skip to main content

Advertisement

Commentary/Editorials

Section edited by Christian Capitini, MD

Reaction to and/or perspectives on significant events in the field in the basic science area. May address a critical challenge, elaborate or extend a conversation of a focal article, provide an application of a theoretical perspective, or shed light on a particular issue in the field.

  1. Programmed cell death protein 1 (PD-1) blockade is only effective in a minority of patients, prompting the search for combinatorial therapies that increase responses. Identifying effective combinations require...

    Authors: Sandra Demaria, Emanuela Romano, Muriel Brackstone and Silvia C. Formenti

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:318

    Content type: Commentary

    Published on:

  2. Immune checkpoint blockers (ICB) have revolutionized cancer therapy. However, complete response is observed in a minority of patients and most patients develop immune-related adverse events (irAEs). These incl...

    Authors: Anne Montfort, Carine Dufau, Céline Colacios, Nathalie Andrieu-Abadie, Thierry Levade, Thomas Filleron, Jean-Pierre Delord, Maha Ayyoub, Nicolas Meyer and Bruno Ségui

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:303

    Content type: Commentary

    Published on:

  3. The tremendous clinical success of immune checkpoint inhibition (ICI), particularly targeting the programmed cell death protein 1 (PD-1)/programmed death-ligand 1/2 (PD-L1/2) pathway, has resulted in applicati...

    Authors: Catherine T. Le and William J. Murphy

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:291

    Content type: Commentary

    Published on:

  4. Sensitivity to immune checkpoint inhibitor (ICPI) therapy is governed by a complex interplay of tumor and host-related determinants. Epidemiological studies have highlighted that exposure to antibiotic therapy...

    Authors: David J. Pinato, Daria Gramenitskaya, Daniel M. Altmann, Rosemary J. Boyton, Benjamin H. Mullish, Julian R. Marchesi and Mark Bower

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:287

    Content type: Commentary

    Published on:

  5. Advances in the immunotherapy of cancer have prolonged survival for cancer patients, but the clinical and financial impact of treatments must be considered in determining the overall clinical utility and econo...

    Authors: Peter Paul Yu, Omar Eton and Louis P. Garrison

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:235

    Content type: Commentary

    Published on:

  6. Tumor mutational burden (TMB) assessment is at the forefront in precision medicine. The TMB could represent a biomarker for immune checkpoint inhibitors (ICIs) responses. Whole exome sequencing (WES) is the go...

    Authors: Hao-Xiang Wu, Zi-Xian Wang, Qi Zhao, Feng Wang and Rui-Hua Xu

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:206

    Content type: Commentary

    Published on:

  7. Primary adrenal failure (Addison’s disease) is a rare complication of immune checkpoint inhibitor (ICI) therapy. Untreated – and also sometimes under adequate hydrocortisone replacement therapy – the levels of...

    Authors: Igor Alexander Harsch

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:166

    Content type: Hypothesis

    Published on:

  8. Recent phase 1–2 trials reported manageable safety profiles and promising antitumor activities of anti-PD-1 drugs (pembrolizumab, nivolumab, camrelizumab and JS001) with/without chemotherapy in recurrent/metas...

    Authors: Jia-Wei Lv, Jun-Yan Li, Lin-Na Luo, Zi-Xian Wang and Yu-Pei Chen

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:159

    Content type: Commentary

    Published on:

  9. Patients with human immunodeficiency virus (HIV) infection have a high risk of developing virally-mediated cancers. These tumors have several features that could make them vulnerable to immune checkpoint inhib...

    Authors: Jacob J. Adashek, Pedro Nazareth Aguiar Junior, Natalie Galanina and Razelle Kurzrock

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:130

    Content type: Commentary

    Published on:

  10. Pembrolizumab monotherapy has become the preferred treatment for patients with advanced non-small cell lung carcinoma (NSCLC) and a programmed cell death-ligand 1 (PD-L1) tumor proportion score (TPS) of at lea...

    Authors: Yixin Zhou, Zuan Lin, Xuanye Zhang, Chen Chen, Hongyun Zhao, Shaodong Hong and Li Zhang

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:120

    Content type: Commentary

    Published on:

  11. Malignant pleural effusions (MPE) are a common terminal pathway for many cancers, with an estimated United States incidence of more than 150,000 cases per year. MPE is an aggressive disease with a uniformly fa...

    Authors: Albert D. Donnenberg, James D. Luketich, Rajeev Dhupar and Vera S. Donnenberg

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:110

    Content type: Commentary

    Published on:

  12. Formenti et al. have recently reported the clinical outcomes and translational readouts of a trial of the anti-CTLA-4 inhibitor, ipilimumab, in combination with palliative radiotherapy in 39 patients with non-...

    Authors: Anna Wilkins, Fiona McDonald, Kevin Harrington and Alan Melcher

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:64

    Content type: Commentary

    Published on:

  13. Oncolytic viruses are an emerging class of immunotherapy agents for cancer treatment. In this issue of JITC, Machiels et al. reports early phase data from an oncolytic adenovirus given by intravenous (IV) admi...

    Authors: Howard L. Kaufman and Praveen K. Bommareddy

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:26

    Content type: Commentary

    Published on:

  14. Tumors responding to immune checkpoint inhibitors (ICIs) have a higher level of immune infiltrates and/or an Interferon (IFN) signature indicative of a T-cell-inflamed phenotype. Melanoma and lung cancer demon...

    Authors: Saman Maleki Vareki

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:157

    Content type: Commentary

    Published on:

  15. Immune checkpoint inhibitors which activate the host’s immune system to fight cancer have brought dramatic improvements to the overall survival of a growing number of deadly malignancies. Their use comes at th...

    Authors: Khashayar Esfahani

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:154

    Content type: Commentary

    Published on:

  16. Unlike chemotherapy treatments that target the tumor itself (rather nonspecifically), immune-based therapies attempt to harness the power of an individual patient’s immune system to combat cancer. Similar to c...

    Authors: Shanta Bantia and Nirmal Choradia

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:143

    Content type: Commentary

    Published on:

    The Correction to this article has been published in Journal for ImmunoTherapy of Cancer 2019 7:56

  17. Commentary on « Ipilimumab induced vasculitis » by Padda A. et al., J Immunother Cancer. 2018;6:12. The authors diagnosed a small vessel vasculitis following treatment with anti-CTLA-4 (ipilimumab) for a resec...

    Authors: Thibault Comont, Vincent Sibaud, Loïc Mourey, Pierre Cougoul and Odile Beyne-Rauzy

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:120

    Content type: Commentary

    Published on:

  18. An updated survival analysis by Callahan et al. published in the February 1, 2018 issue of the Journal of Clinical Oncology reported a 3-year overall survival (OS) rate of 63% for 94 patients with previously trea...

    Authors: Mark R. Albertini

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:80

    Content type: Commentary

    Published on:

  19. Anti-cancer immunotherapy is encountering its own checkpoint. Responses are dramatic and long lasting but occur in a subset of tumors and are largely dependent upon the pre-existing immune contexture of indivi...

    Authors: Tolga Turan, Deepti Kannan, Maulik Patel, J. Matthew Barnes, Sonia G. Tanlimco, Rongze Lu, Kyle Halliwill, Sarah Kongpachith, Douglas E. Kline, Wouter Hendrickx, Alessandra Cesano, Lisa H. Butterfield, Howard L. Kaufman, Thomas J. Hudson, Davide Bedognetti, Francesco Marincola…

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:50

    Content type: Hypothesis

    Published on:

  20. Immune checkpoint inhibitors have emerged as a promising therapeutic option for metastatic cancers. However, they have been associated with inflammatory adverse reactions in various organ systems. A recent art...

    Authors: Marc-Elie Nader, Jeffrey N. Myers and Paul W. Gidley

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:24

    Content type: Commentary

    Published on:

  21. Inbred mice are the mainstay for preclinical cancer assessment of potential therapeutics, especially immune-based approaches. However, the use of young, lean, inbred mice housed under specific-pathogen-free co...

    Authors: William J. Murphy

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:88

    Content type: Commentary

    Published on:

  22. The recent use of T cell-based cancer immunotherapies, such as adoptive T-cell transfer and checkpoint blockade, yields increasing clinical benefit to patients with different cancer types. However, decrease of...

    Authors: Sonia T. Chelbi and Greta Guarda

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:39

    Content type: Commentary

    Published on:

  23. The Common Rule is a set of ethical principles that provide guidance on the management of human subjects taking part in biomedical and behavioral research in the United States. The elements of the Common Rule ...

    Authors: Howard L. Kaufman, Lisa H. Butterfield, Pierre G. Coulie, Sandra Demaria, Robert L. Ferris, Jérôme Galon, Samir N. Khleif, Ira Mellman, Pamela S. Ohashi, Willem W. Overwijk, Suzanne L. Topalian and Francesco M. Marincola

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:37

    Content type: Commentary

    Published on:

  24. Mounting an immune response sufficient to eradicate a tumor is the goal of modern immunotherapy. Single agent therapies with checkpoint inhibitors or costimulatory molecule agonists are effective only for a sm...

    Authors: Stefanie N. Linch and William L. Redmond

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:31

    Content type: Commentary

    Published on:

  25. The recent study by Hodi et al. published in the Journal of Clinical Oncology has evaluated unconventional response patterns during PD-1 inhibitor therapy using immune-related response criteria (irRC) in compa...

    Authors: Mizuki Nishino

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:30

    Content type: Commentary

    Published on:

  26. Attention has recently focused on new cancer immunotherapy protocols aiming to activate T cell mediated anti-tumor responses. To this end, administration of antibodies that target inhibitory molecules regulati...

    Authors: Per thor Straten and Federico Garrido

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:23

    Content type: Commentary

    Published on:

  27. Advances in cancer immunotherapy are leading to its increasing and successful application for the treatment of solid–tissue cancers. Despite the recent advances there are still significant barriers, in particu...

    Authors: Steven K. Grossenbacher, Robert J. Canter and William J. Murphy

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:19

    Content type: Commentary

    Published on:

  28. The innate and adaptive immune systems have evolved together to fight infection and cancerous tissues. The innate immune system emerges first with the adaptive immune system following, both ostensibly being br...

    Authors: Carolyn Rosinsky and Paul Andrew Antony

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:16

    Content type: Commentary

    Published on:

  29. Reliable mouse models are key in the discovery and development of novel anticancer treatments. Non-invasive monitoring techniques such as bioluminescence imaging (BLI) are useful tools to determine tumor engra...

    Authors: Thaïs Baert, Tina Verschuere, Anaïs Van Hoylandt, Rik Gijsbers, Ignace Vergote and An Coosemans

    Citation: Journal for ImmunoTherapy of Cancer 2015 3:57

    Content type: Commentary

    Published on:

Annual Journal Metrics

Advertisement